Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 4,209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Active, not recruiting Phase 2 Interventional

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998
View directory record Official record
Conditions
Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions
Enobosarm, Semaglutide (Wegovy) weekly injection
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
65 Years to 100 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

NCT04462198
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
PIPE-505, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Torrance, California • Boca Raton, Florida • New Albany, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Anakinra 100 mg, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

NCT07291232
View directory record Official record
Conditions
Obesity
Interventions
ABBV-295, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

NCT04570384
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
L-Citrulline, Placebo
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RJV001 Study in Adults Receiving Abdominoplasty

NCT04821648
View directory record Official record
Conditions
Submental Fat (SMF), Double Chin
Interventions
RJV001, Placebo
Drug
Lead sponsor
Rejuven Dermaceutical Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

NCT02067793
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NRX-1074 1 mg, Placebo, NRX-1074 5 mg, NRX-1074 10 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Oakland, California • Skokie, Illinois • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

NCT02496221
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide 50 mg, Placebo, CCK (Kinevac)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

NCT00709904
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 21, 2026, 10:34 PM EDT
Active, not recruiting Phase 3 Interventional

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609
View directory record Official record
Conditions
Angelman Syndrome
Interventions
obudanersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 4 Interventional

iPACK Block With Dexamethasone For Total Knee Replacement

NCT04917055
View directory record Official record
Conditions
Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Interventions
ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

NCT01281839
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversing Type 1 Diabetes After it is Established

NCT01106157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globin (ATG), Placebo, Pegylated GCSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Recruiting Phase 2 Interventional

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081
View directory record Official record
Conditions
Atrial Fibrillation, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

NCT00234507
View directory record Official record
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 21, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 21, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pertussis Vaccine in Healthy Pregnant Women

NCT00707148
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
4
States / cities
Durham, North Carolina • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 21, 2026, 10:34 PM EDT